Effects of topical methotrexate loaded gold nanoparticle in cutaneous inflammatory mouse model

Fratoddi, Ilaria; Benassi, Luisa; Botti, Elisabetta; Vaschieri, Cristina; Venditti, Iole; Bessar, Hagar; Samir, Maie A.; Azzoni, Paola; Magnoni, Cristina; Costanzo, Antonio; Casagrande, Viviana; Federici, Massimo; Bianchi, Luca; Pellacani, Giovanni

doi:10.1016/j.nano.2019.01.006

Cited by 45 publications

(31 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…AuNPs can be synthesized by means of several processes such as chemical, physical, and biological methods [24,[49][50][51]65]. A well-known bottom-up approach is a wet reduction in the presence of a capping agent [55,57,[59][60][61][62]64]. The obtained AuNPs can be easily investigated by microscope techniques, such as transmission electron microscope (TEM), scanning electron microscope (SEM), and atomic force microscope (AFM) [98][99][100][101][102].…”

Section: Aunpsmentioning

confidence: 99%

Gold Nanoparticles and Nanorods in Nuclear Medicine: A Mini Review

et al. 2019

Self Cite

View full text Add to dashboard Cite

In the last decade, many innovative nanodrugs have been developed, as well as many nanoradiocompounds that show amazing features in nuclear imaging and/or radiometabolic therapy. Their potential uses offer a wide range of possibilities. It can be possible to develop nondimensional systems of existing radiopharmaceuticals or build engineered systems that combine a nanoparticle with the radiopharmaceutical, a tracer, and a target molecule, and still develop selective nanodetection systems. This review focuses on recent advances regarding the use of gold nanoparticles and nanorods in nuclear medicine. The up-to-date advancements will be shown concerning preparations with special attention on the dimensions and functionalizations that are most used to attain an enhanced performance of gold engineered nanomaterials. Many ideas are offered regarding recent in vitro and in vivo studies. Finally, the recent clinical trials and applications are discussed.Radiopharmaceuticals are showing amazing outcomes in diagnostic (90%) and therapeutic (10%) applications for many diseases such as cancer, heart and brain diseases, and so on [33]. They consist of a radioactive nuclide linked to a biologically active molecule directed to the target of interest. When radionuclides emit γ rays (either directly, as pure γ emitters, or indirectly, as β+ emitters), the radiopharmaceutical is intended for diagnostic imaging. When radionuclides emit β− or α particles (thanks to the cell-damaging properties) the radiopharmaceutical is used for therapeutic applications and, in some recent research studies, even for radio-guided surgery [34][35][36]. Theragnostics is a new term that implies the use of the same molecule, labeled with different radionuclides, for both diagnostic and therapeutic purposes [37][38][39].Radiopharmaceuticals have been increasingly used for medical diagnosis since the late 1940s, when nuclear medicine was born. Nuclear medicine aims at evaluating both physiological function as well as biochemical changes in disease conditions; it includes two-dimensional (2D) imaging (planar scintigraphy) and three-dimensional (3D) imaging (single-photon emission computed tomography, SPECT, and positron emission tomography, PET). The functional information obtained by SPECT and PET may need to be coupled with the anatomic/morphologic information typically provided by computed tomography (CT) (hence SPECT and PET are now commonly called SPECT-CT and PET-CT): these approaches, named "hybrid imaging", have many advantages as well as high sensitivity, good spatial resolution, and the possibility to correctly locate functional abnormalities (by the SPECT or PET component) within a definite anatomic field (by the CT component) [34].The γ-emitting radionuclides that are used for planar and SPECT imaging are usually obtained within hospital nuclear medicine facilities (or research departments) from small portable generators; some are produced by nuclear reactors and then shipped to the hospital facility ready to use. The β+ emitting radionuclides ...

show abstract

Section: Aunpsmentioning

confidence: 99%

Gold Nanoparticles and Nanorods in Nuclear Medicine: A Mini Review

et al. 2019

Self Cite

View full text Add to dashboard Cite

show abstract

“…The amount of methotrexate present in the different skin layers was found to be increased compared to the drug alone. Furthermore, the compounds were safe and able to penetrate the skin barrier (Bessar et al, ; Fratoddi et al, ).…”

Section: Nanotherapeutics For Psoriasis: Nanocarriers Nanodrugs and mentioning

confidence: 99%

Nanodermatology‐based solutions for psoriasis: State‐of‐the art and future prospects

Damiani

Pacifico

Linder

et al. 2019

Dermatologic Therapy

View full text Add to dashboard Cite

Nanodermatology is an emerging, multidisciplinary science, arising from the convergence of nanotechnology, pharmacology, physics/biophysics, chemistry/biochemistry, chemical engineering, material science, and clinical medicine. Nanodermatology deals with (a) skin biology, anatomy, and physiology at the nanoscale (“skin nanobiology”), (b) diagnosis performed by means of novel diagnostic devices, assisted by nanobiotechnologies (“nanodiagnosis”), and (c) treatment through innovative therapeutic agents, including phototherapy (“photonanotherapy”/“photonanodermatology”) and systemic/topical drug administration (“nanotherapy”) at the nanoscale, and drug delivery—such as transdermal or dermal drug delivery (TDDD/DDD)—enhanced and improved by nanostructures and nanodrugs (“nanodrug delivery”). Nanodermatology, as a super‐specialized branch of dermatology, is a quite recent specialty: the “Nanodermatology Society” founded by the eminent dermatologist Dr. Adnan Nasir, was established in 2010, with the aim of bringing together different stakeholders, including dermatologists, nanotechnology scientists, policy‐makers and regulators, as well as students and medical residents. Psoriasis has a prevalence of 2–3% worldwide and imposes a severe clinical and societal burden. Nanodermatology‐based solutions appear promising for the proper treatment and management of psoriasis, assisting and enhancing different steps of the process of health‐care delivery: from the diagnosis to the therapeutics, paving the way for a personalized approach, based on the specific dysregulated biomarkers.

show abstract

“…The coupling of MTX to GNPs (MTX-GNPs) was reported to facilitate effective penetration through the human skin barrier in an ex vivo system (Bessar et al, 2016). Recently, the topical administration of MTX-GNPs was shown to mitigate psoriatic skin inflammation, accompanied by a decrease in proliferation and CD8 þ T cell numbers, in a murine model (Fratoddi et al, 2019). However, the effect of MTX-GNPs on immune cells and human skin, as well as the detailed mechanism behind it remains unknown.…”

Section: Introductionmentioning

confidence: 99%

Nanoparticle-Coupled Topical Methotrexate Can Normalize Immune Responses and Induce Tissue Remodeling in Psoriasis

Özcan

Şahin

Impellizzieri

et al. 2020

Journal of Investigative Dermatology

View full text Add to dashboard Cite

Methotrexate (MTX) is an antiproliferative drug used for treating inflammatory diseases, including psoriasis. Nevertheless, its use in localized therapy is hindered because of poor transdermal penetration. We show that MTX coupled with gold nanoparticles (GNPs) demonstrates superior antiinflammatory efficacy than MTX alone in an imiquimod-induced mouse model, significantly reducing gd T cells, CD4 þ T cells, and neutrophils. Furthermore, it was well tolerated upon systemic and topical administration. In an AGR129 human xenograft mouse model, two-week topical treatment with MTX-GNPs inhibited skin hyperplasia significantly better than topical calcipotriol-betamethasone and led to profound tissue remodeling, involving the upregulation of extracellular matrix reorganization and the downregulation of cornification and keratinization processes. The number of resident T cells in the grafts, as well as interleukin-17 production, drastically decreased upon MTX-GNP treatment. While both MTX and MTX-GNPs directly prevented the proliferation and induced apoptosis of T cells, the suppression of cytokine production was a shared mechanism of GNP and MTX-GNPs. In conclusion, MTX-GNPs influence immune and stromal components of the skin, leading to the potent inhibition of pathogenesis in preclinical psoriasis. MTX-GNPs surpass the efficacy of conventional MTX and standard of care, emerging as a non-steroidal, topical alternative for psoriasis treatment.

show abstract

Effects of topical methotrexate loaded gold nanoparticle in cutaneous inflammatory mouse model

Cited by 45 publications

References 45 publications

Gold Nanoparticles and Nanorods in Nuclear Medicine: A Mini Review

Gold Nanoparticles and Nanorods in Nuclear Medicine: A Mini Review

Nanodermatology‐based solutions for psoriasis: State‐of‐the art and future prospects

Nanoparticle-Coupled Topical Methotrexate Can Normalize Immune Responses and Induce Tissue Remodeling in Psoriasis

Contact Info

Product

Resources

About